In parallel, in vivo studies indicated that shRNA-mediated inhibition of semaphorin D expression in breast tumor cells has led to reduced levels of metastasis and longer survival, accompanied by reduced formation of osteolytic skeletal lesions (147). Here, SEMA3A is linked to breast neoplasm.